Skip to main content

Teriparatide

No sources yet

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

HormonesAliases: PTH 1-34, Forteo, rhPTH(1-34)
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on Teriparatide; the papers are listed at the end. Research summary, not a recommendation.

What it is

Teriparatide is the first 34 amino acids of human parathyroid hormone (PTH 1-34), made by recombinant DNA technology. It is an FDA-approved prescription injectable (brand name Forteo, approved 2002) for osteoporosis in people at high risk of fracture. It is the biologically active fragment of the hormone the parathyroid glands use to regulate blood calcium.

How it works

Teriparatide binds the PTH type 1 receptor on bone cells. Continuous PTH exposure breaks bone down, but brief daily pulses tip the balance toward bone formation: osteoblast activity and bone formation markers rise before resorption markers do (the 'anabolic window'), so trabecular bone mass and microarchitecture improve over months of use.

What it has been studied for

  • vertebral and non-vertebral fracture reduction in postmenopausal osteoporosis
  • osteoporosis in men and glucocorticoid-induced osteoporosis
  • comparison against bisphosphonates in severe osteoporosis
  • bone density gain measured by DXA

Strength of the evidence

Approved drugFDA-approved since 2002 with randomized placebo-controlled fracture-outcome trials in thousands of patients.

What the literature reports on safety

The pivotal trial reported more nausea, headache, dizziness and leg cramps than placebo and transient rises in serum calcium. A rat study found osteosarcoma at high lifetime exposure, which led to a boxed warning that the FDA removed in 2020 after post-marketing surveillance found no excess of osteosarcoma; long-term primate studies found no bone tumours. The label advises against use in people with Paget's disease, bone cancers, prior skeletal radiation, or unexplained high alkaline phosphatase. It is a prescription drug and should only be used under a physician's care.

Key papers

  1. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates. (opens in a new tab)

    Review · Krege JH, Gilsenan AW, et al. · JBMR Plus (2022) · PMID 36111201

    Traced the rat osteosarcoma finding, the primate and human surveillance data that followed, and the 2020 FDA label update that removed the boxed warning.

  2. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. (opens in a new tab)

    Randomized trial · Neer RM, Arnaud CD, Zanchetta JR et al · N Engl J Med (2001) · PMID 11346808

    In 1,637 postmenopausal women with prior vertebral fractures, daily PTH(1-34) cut new vertebral fractures by about two-thirds and non-vertebral fragility fractures by about half versus placebo over a median 21 months, while raising spine bone density.

  3. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. (opens in a new tab)

    Randomized trial · Kendler DL, Marin F, Zerbini CAF et al · Lancet (2018) · PMID 29129436

    Head-to-head against the bisphosphonate risedronate in 1,360 women with severe osteoporosis, teriparatide produced fewer new vertebral fractures and fewer clinical fractures over 24 months.

  4. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. (opens in a new tab)

    Cohort study · Gilsenan A, Midkiff K, et al. · J Bone Miner Res (2021) · PMID 32990990

    Fifteen years of US cancer-registry surveillance found no increase in adult osteosarcoma among people treated with teriparatide compared with the background rate.

  5. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. (opens in a new tab)

    Animal study · Vahle JL, Zuehlke U, Schmidt A et al · J Bone Miner Res (2008) · PMID 18684088

    Eighteen months of teriparatide in monkeys, followed by three years off drug, produced no bone tumours and lasting bone gains, which is part of why the rat osteosarcoma signal is read as species-specific.

Sources checked: PubMed esummary for every PMID and doi.org resolution for every DOI, checked 2026-11-06; Drugs@FDA application NDA 021318 (Forteo approval history and current label) read for the safety notes., written 2026-11-06.

No sources yet

None of the three teachers' sources we have indexed discuss Teriparatide yet. This page will fill in as sources are added.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

Teriparatide — Hunter, Taylor, Bachmeyer | Reset Biology